Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free RYM Stock Alerts

RYTHM (RYM) Competitors

RYTHM logo
$20.80 -1.42 (-6.39%)
Closing price 03:57 PM Eastern
Extended Trading
$20.90 +0.10 (+0.48%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RYM vs. DERM, ACB, LFCR, LENZ, and AARD

Should you buy RYTHM stock or one of its competitors? RYTHM's main competitors and comparable companies include Journey Medical (DERM), Aurora Cannabis (ACB), Lifecore Biomedical (LFCR), LENZ Therapeutics (LENZ), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does RYTHM compare to Journey Medical?

RYTHM (NASDAQ:RYM) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, Journey Medical had 20 more articles in the media than RYTHM. MarketBeat recorded 22 mentions for Journey Medical and 2 mentions for RYTHM. RYTHM's average media sentiment score of 1.31 beat Journey Medical's score of 0.54 indicating that RYTHM is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RYTHM
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Journey Medical
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Journey Medical has higher revenue and earnings than RYTHM. Journey Medical is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RYTHM$17.28M2.62-$33.26M-$10.53N/A
Journey Medical$68.18M2.71-$11.43M-$0.22N/A

RYTHM has a net margin of -6.20% compared to Journey Medical's net margin of -8.95%. RYTHM's return on equity of -12.57% beat Journey Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
RYTHM-6.20% -12.57% -2.60%
Journey Medical -8.95%-20.23%-6.60%

6.0% of RYTHM shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

RYTHM has a beta of 9.47, suggesting that its share price is 847% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Journey Medical has a consensus price target of $14.00, indicating a potential upside of 108.33%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts clearly believe Journey Medical is more favorable than RYTHM.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Journey Medical beats RYTHM on 10 of the 16 factors compared between the two stocks.

How does RYTHM compare to Aurora Cannabis?

RYTHM (NASDAQ:RYM) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, Aurora Cannabis had 21 more articles in the media than RYTHM. MarketBeat recorded 23 mentions for Aurora Cannabis and 2 mentions for RYTHM. RYTHM's average media sentiment score of 1.31 beat Aurora Cannabis' score of 0.62 indicating that RYTHM is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RYTHM
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aurora Cannabis
8 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

RYTHM has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RYTHM$17.28M2.62-$33.26M-$10.53N/A
Aurora Cannabis$314.07M0.76-$88.13M-$1.41N/A

RYTHM has a net margin of -6.20% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat RYTHM's return on equity.

Company Net Margins Return on Equity Return on Assets
RYTHM-6.20% -12.57% -2.60%
Aurora Cannabis -32.26%4.37%3.45%

RYTHM has a beta of 9.47, indicating that its stock price is 847% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

Aurora Cannabis beats RYTHM on 9 of the 16 factors compared between the two stocks.

How does RYTHM compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

RYTHM has a net margin of -6.20% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat RYTHM's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifecore Biomedical-29.93% N/A -16.16%
RYTHM -6.20%-12.57%-2.60%

Lifecore Biomedical currently has a consensus target price of $6.50, suggesting a potential upside of 37.71%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, equities analysts clearly believe Lifecore Biomedical is more favorable than RYTHM.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifecore Biomedical
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

RYTHM has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifecore Biomedical$128.87M1.39-$40.50M-$1.07N/A
RYTHM$17.28M2.62-$33.26M-$10.53N/A

In the previous week, RYTHM had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 2 mentions for RYTHM and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat RYTHM's score of 1.31 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company Overall Sentiment
Lifecore Biomedical Very Positive
RYTHM Positive

Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.47, meaning that its stock price is 847% more volatile than the broader market.

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lifecore Biomedical beats RYTHM on 9 of the 16 factors compared between the two stocks.

How does RYTHM compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

LENZ Therapeutics currently has a consensus price target of $28.80, indicating a potential upside of 508.88%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than RYTHM.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

LENZ Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, RYTHM has a beta of 9.47, suggesting that its stock price is 847% more volatile than the broader market.

RYTHM has a net margin of -6.20% compared to LENZ Therapeutics' net margin of -586.74%. RYTHM's return on equity of -12.57% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-586.74% -53.39% -49.14%
RYTHM -6.20%-12.57%-2.60%

RYTHM has lower revenue, but higher earnings than LENZ Therapeutics. RYTHM is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M7.79-$82.13M-$4.09N/A
RYTHM$17.28M2.62-$33.26M-$10.53N/A

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 17 more articles in the media than RYTHM. MarketBeat recorded 19 mentions for LENZ Therapeutics and 2 mentions for RYTHM. RYTHM's average media sentiment score of 1.31 beat LENZ Therapeutics' score of 0.35 indicating that RYTHM is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
RYTHM
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

LENZ Therapeutics beats RYTHM on 10 of the 16 factors compared between the two stocks.

How does RYTHM compare to Aardvark Therapeutics?

RYTHM (NASDAQ:RYM) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

6.0% of RYTHM shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aardvark Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Aardvark Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
RYTHM-6.20% -12.57% -2.60%
Aardvark Therapeutics N/A -71.54%-64.94%

RYTHM has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RYTHM$17.28M2.62-$33.26M-$10.53N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$3.21N/A

RYTHM has a beta of 9.47, suggesting that its share price is 847% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.81, suggesting that its share price is 281% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 4 more articles in the media than RYTHM. MarketBeat recorded 6 mentions for Aardvark Therapeutics and 2 mentions for RYTHM. RYTHM's average media sentiment score of 1.31 beat Aardvark Therapeutics' score of 1.26 indicating that RYTHM is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RYTHM
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aardvark Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aardvark Therapeutics has a consensus target price of $16.30, indicating a potential upside of 149.24%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than RYTHM.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aardvark Therapeutics
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46

Summary

RYTHM and Aardvark Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get RYTHM News Delivered to You Automatically

Sign up to receive the latest news and ratings for RYM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RYM vs. The Competition

Export
MetricRYTHMPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$48.43M$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio-1.98775.15269.0625.28
Price / Sales2.62743.50592.5787.62
Price / CashN/A66.4570.4850.90
Price / Book1.1611.6012.916.24
Net Income-$33.26M$2.77B$3.45B$347.60M
7 Day Performance-7.56%0.17%1.12%1.07%
1 Month Performance-8.05%0.35%1.79%1.03%
1 Year PerformanceN/A161.52%67.69%20.77%

RYTHM Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RYM
RYTHM
1.1258 of 5 stars		$20.80
-6.4%		N/AN/A$48.43M$17.28MN/A140
DERM
Journey Medical
2.9277 of 5 stars		$6.44
-0.4%		$13.00
+101.8%		-8.3%$178.15M$61.86MN/A90
ACB
Aurora Cannabis
1.4551 of 5 stars		$2.81
-0.7%		N/A-31.5%$175.30M$247.82MN/A1,028
LFCR
Lifecore Biomedical
1.9591 of 5 stars		$4.35
-0.9%		$6.50
+49.4%		-38.9%$164.67M$128.87MN/A690
LENZ
LENZ Therapeutics
3.0861 of 5 stars		$5.05
+1.2%		$29.80
+490.1%		-88.3%$156.62M$19.09MN/A110

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RYM) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...
TradeSmith | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
How a rare metal shortage sent gains up 2512 percent
In 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...
Awesomely | Sponsoredtc pixel